The Jenex Corporation
The Jenex Corporation
- ISIN: CA4760231064
- Land: .
Nachricht vom 12.10.2017 | 19:12
The Jenex Corporation Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)
DGAP-News: The Jenex Corporation / Key word(s): Miscellaneous
Toronto, Ontario--(Newsfile Corp. - October 12, 2017) - The Jenex Corporation (TSXV: JEN.H) ('Jenex' or the 'Company'), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap™.
Dr. Alyson Kelvin at UHN reported the following:
'To evaluate the effectiveness of the Jenex TherOZap™ device against the infectivity of Zika virus, cells were infected with a range of Zika virus doses and treated with the Jenex device with heat. In the cells that received the lowest viral dose, initial results showed infected cells that had been treated with the Jenex TherOZap™ device had a markedly lower cytopathic effect compared to infected cells that did not receive treatment. These preliminary results need to be confirmed through repeated testing as well as by measurement of virus viability. Cytopathic effect is a measure of cellular pathogenesis and cellular viability in relation to viral infection; results of a viral replication assay and measurements of live viral activity are pending.'
Mr. Rob Fia, CEO, commented:
'We are pleased with the initial test results on the Zika Virus with our patent pending TherOZap™ technology. Jenex is excited about these initial tests results and we look forward to further data as it becomes available from Techna Institute at UHN. Jenex will have more to report to over the next several weeks.'
Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.
Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.
About Techna Institute:
Techna is an institute of the University Health Network, in collaboration with the University of Toronto, focused on the accelerated development and exploitation of technology for improved health. Techna is designed to shorten the time interval from technology discovery and development to application for the benefit of patients and the health care system. It also stimulates and facilitates the innovation cycle through a continuum of clinically driven innovation, technology & process development, and translational research. For more information visit: technainstitute.com.
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute 'forward-looking' statements. These statements relate to future events or the Company's future performance and include laboratory tests involving TherOZap™, as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company may not complete the commercialization or marketing of its products as described in this news or attract capital in the future. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
For further information please contact:
NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/29660
|Company:||The Jenex Corporation|
|End of News||DGAP News Service|
mic AG: „Lassen Sie sich überraschen!“
Neustart für die mic AG: Mit frischem Kapital will die Münchner Beteiligungsgesellschaft neue Wachstumsfelder in den Bereichen Blockchain und Fintech erschließen: „Mit einer großen Gesellschaft in der Softwareentwicklung im Blockchain-Bereich bin ich in konkreten Verhandlungen“, verrät mic-Vorstand Andreas Empl im Interview mit Financial.de. Die mic-Aktie sieht er weit unter Wert gehandelt: „Dem jetzigen Portfoliowert von über 20 Mio. Euro steht eine Börsenbewertung von nur rund 10 Mio. Euro gegenüber.“
GBC im Fokus
M1 Kliniken AG: Kursziel angehoben
Die M1 Kliniken AG hat den eingeschlagenen Wachstumskurs mit einem Umsatzanstieg von 20,3 % auch im ersten Halbjahr fortgesetzt. Analog dazu gelang es der Gesellschaft, einen überproportionalen Anstieg des EBIT um 36,5% zu erreichen und unsere Erwartungen zu übertreffen. Wir haben auf dieser Grundlage unsere Umsatz- und Ergebnisschätzungen angehoben. Bei einem Kursziel von 16,15 € ergibt sich ein hohes Kurspotenzial - damit lautet das Rating KAUFEN.
Der AKTIONÄR News
20. Oktober 11:07 Air Berlin, Lufthansa und Ryanair: Wie Anleger jetzt handeln sollten
20. Oktober 11:00 DAX 15.000 – Alle 30 DAX-Aktien im Check: Bei diesen Werten geht die ...
20. Oktober 10:07 BB Biotech schlägt erneut Benchmark in Q3 – Branche mit wichtigen ...
20. Oktober 10:05 Schock verdaut - DAX macht sich auf den Weg nach oben
20. Oktober 09:35 Super-Aktie Paypal: Ganz starke Leistung
News im Fokus
Vonovia SE: Vonovia und die französische Groupe SNI unterzeichnen Partnerschaftsvereinbarung (News mit Zusatzmaterial)
18. Oktober 2017, 12:50
Memorandum of Understanding Signed with France’s Largest Residential Landlord Société Nationale Immobilière (SNI)
18. Oktober 2017
Original-Research: FinTech Group AG (von GBC AG): Kaufen
19. Oktober 2017